Lacey Litchfield

Articles by Lacey Litchfield

100 Imlunestrant Plus Abemaciclib Versus Fulvestrant Plus Abemaciclib in Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2–) Advanced Breast Cancer (ABC): An Indirect Treatment Comparison (ITC) of Three Phase 3 Trials

ByKomal L. Jhaveri,Francois Clement Bidard,Kevin Kalinsky, MD, MS,Patrick Neven, MD, PhD,Hope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Lacey Litchfield,Christoph Cramer von Laue,Sory Traore,Francisco Sapunar,Yujia Li,Joyce O’Shaughnessy, MD

May 21st 2026

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

How Significant is the Approval of Daraxonrasib in Pancreatic Cancer?

Biomarker-Independent ADC Rina-S Advances to Phase 3 in Endometrial Cancer

Where Do CELMoDs Fit With CAR T Cells and Bispecifics in Multiple Myeloma?

sNDA for Gedatolisib Submitted to FDA in PIK3CA-Mutant Breast Cancer